-
COMy 2026 | Honoring the Architects of Progress: Major Awards Spotlight the Past, Present, and Future of Multiple Myeloma Research
From May 14–17, 2026, the 12th International Congress on Controversies in Multiple Myeloma (COMy 2026) was successfully held in Paris, France. Recognized as one of the most influential academic meetings in the field of multiple myeloma (MM), COMy has long been distinguished by its focused format, in-depth scientific discussions, and emphasis on unresolved clinical questions.
-
Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs
From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Dr. Ludovico Docimo, Professore Ordinario e Primario of the UOC of General, Minimally Invasive and Obesity Surgery at the University of Campania “Luigi Vanvitelli” (Italy), shared his view that robotic surgery will transform colorectal operating rooms,…
-
CRC Cooperation Between Italy and China: Insights from Dr. Federico Maria Mongardini
From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Prof. Federico Maria Mongardini from PIO XI Hospital, Italy – attending the symposium for the third consecutive year – shared his insights on multimodal deep learning, obesity management, and Italy‑China collaboration.
-
From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer
On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was convened in Hangzhou, Zhejiang Province. Prof. Zhang Suzhan from the Second Affiliated Hospital, Zhejiang University School of Medicine attended the meeting and shared his insights on colorectal cancer screening, precision MDT management, and localized Chinese clinical solutions.
-
ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer
CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line treatment for HR-positive/HER2-negative advanced breast cancer and have significantly improved patient outcomes. However, in real-world clinical practice, a subset of patients still experiences rapid disease progression early during treatment, suggesting the presence of more aggressive tumor biology and potential intrinsic endocrine resistance mechanisms.
-
Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era
Against the backdrop of Chongqing’s mountainous skyline and flowing rivers, the 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference were successfully held in Chongqing from April 15–19, 2026.
-
ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody
On May 8, local time, at the ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Jian Zhang from Fudan University Shanghai Cancer Center delivered a rapid oral presentation of efficacy and safety results from the Phase II expansion cohort evaluating the PD-L1×VEGF-A bispecific antibody Pumitamig in combination with the TROP2 antibody-drug conjugate (ADC) BNT325…
-
ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer
Trastuzumab deruxtecan (T-DXd) has dramatically reshaped the treatment landscape for advanced HER2-positive breast cancer because of its outstanding efficacy. It is now considered the standard second-line treatment for HER2-positive advanced breast cancer and has also demonstrated remarkable activity in both the first-line metastatic and early breast cancer settings.
Connecting Medical Expertise through Media